IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.245
NA - Nord America 1.161
AS - Asia 303
OC - Oceania 4
AF - Africa 1
Totale 2.714
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.157
IT - Italia 406
IE - Irlanda 317
SE - Svezia 266
CN - Cina 228
DE - Germania 62
AT - Austria 52
FI - Finlandia 34
FR - Francia 32
IN - India 29
BE - Belgio 20
SG - Singapore 18
TR - Turchia 16
GB - Regno Unito 15
RU - Federazione Russa 11
CZ - Repubblica Ceca 8
HK - Hong Kong 5
LU - Lussemburgo 5
UA - Ucraina 5
AU - Australia 4
CA - Canada 4
BG - Bulgaria 2
ID - Indonesia 2
IL - Israele 2
KR - Corea 2
MD - Moldavia 2
NL - Olanda 2
CH - Svizzera 1
JP - Giappone 1
LT - Lituania 1
MK - Macedonia 1
MT - Malta 1
PL - Polonia 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 2.714
Salva come PNG Salva come JPEG
Città #
Dublin 314
Chandler 298
Ann Arbor 123
Ashburn 119
Parma 94
Shanghai 60
New York 56
Vienna 52
Beijing 46
Bologna 44
Bremen 41
Princeton 36
Boardman 31
Dearborn 31
Helsinki 25
Nanjing 24
West Jordan 22
Milan 21
Brussels 18
Verona 18
Des Moines 16
Rio Saliceto 15
Los Angeles 14
Wilmington 14
Fremont 11
Pune 11
Jinan 10
Izmir 9
Trento 9
Ardea 8
Falls Church 8
Guangzhou 8
Rome 8
San Mateo 8
Torrile 8
Hangzhou 7
Hefei 7
Nanchang 7
Boston 6
Houston 6
Kocaeli 6
Reggio Emilia 6
Bolzano 5
Hebei 5
Jiaxing 5
Kunming 5
Redwood City 5
Seattle 5
Verdellino 5
Zhengzhou 5
Brno 4
Busto Arsizio 4
Florence 4
Frankfurt am Main 4
Grafing 4
London 4
Modena 4
Norwalk 4
Trieste 4
Wayne 4
Woodbridge 4
Atlanta 3
Brescia 3
Changsha 3
Collecchio 3
Genova 3
Lanzhou 3
Lonato 3
Melbourne 3
San Giuliano Milanese 3
Scandiano 3
Shenyang 3
Tianjin 3
Washington 3
Alcamo 2
Assago 2
Bagnolo in Piano 2
Bali 2
Bhubaneswar 2
Brooklyn 2
Cambridge 2
Central 2
Cernusco sul Naviglio 2
Cerreto Guidi 2
Chisinau 2
Daejeon 2
Dendermonde 2
Edinburgh 2
Fairfield 2
Fuzhou 2
Haikou 2
Hyderabad 2
Marino 2
Mondavio 2
Monmouth Junction 2
Montreal 2
Neviano degli Arduini 2
Noviglio 2
Piacenza 2
Romainville 2
Totale 1.850
Salva come PNG Salva come JPEG
Nome #
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 111
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 109
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 108
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 92
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 87
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 82
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 79
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 72
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 71
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 71
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 71
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 67
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 66
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 65
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 61
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 61
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 60
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 60
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 59
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 58
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 58
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 57
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 57
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 54
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 54
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 51
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 48
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 45
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 44
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 41
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 41
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 40
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 38
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 38
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 36
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 36
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 35
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 34
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 33
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 31
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 31
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 25
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 25
The radiological appearances of lung cancer treated with immunotherapy: a review 23
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 22
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 21
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 21
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 21
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 20
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 20
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 19
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 18
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 18
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 16
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 14
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 13
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 13
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 11
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 11
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 11
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 11
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 10
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 7
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 6
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 6
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 5
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 5
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 5
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 5
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 4
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 4
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 4
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 3
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 2
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 2
Totale 2.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.690
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 0 0 22 0
2019/2020213 31 12 1 11 15 33 19 15 10 50 9 7
2020/2021237 8 11 9 21 32 33 14 18 22 16 35 18
2021/2022259 13 13 15 19 5 12 55 10 5 10 21 81
2022/20231.277 114 123 68 109 143 140 38 73 382 7 56 24
2023/2024694 32 59 28 35 110 155 96 35 62 80 2 0
Totale 2.833